An observational study in Primary Invasive Breast Cancer, Estrogen Receptor Positive Tumor and Human Epidermal Growth Factor Receptor 2 Negative Tumor, sponsored by North Eastern German Society of Gynaecological Oncology. Active, not recruiting at 40 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by North Eastern German Society of Gynaecological Oncology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 678 studies in Breast Neoplasms with a site in Germany — 114 open to participants now, 196 under way, 81 of them phase 3. Breast Neoplasms · Germany.
Among the 678 studies in Breast Neoplasms with a site in Germany, this one is the 32nd largest by enrollment of the 92 observational ones that give a count, is one of 29 that started in 2018, is one of 93 observational ones, reaches primary completion later than 186 of the 195 other live ones, and was the 416th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →114 of the 678 studies in Breast Neoplasms with a site in Germany are open now. Recruiting first, the newest first:
Institut fuer Frauengesundheit · Sites in Germany
Women only
iOMEDICO AG · Sites in Germany
Ages 18+ · Women only
AstraZeneca · Sites in Germany, United States, France and 6 more countries
Ages 18–130
BeOne Medicines · Sites in Germany, United States, Australia and 13 more countries
Ages 18+
Hoffmann-La Roche · Sites in Germany, United States, Argentina and 23 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
678 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 64 · Phase 2 204 · Phase 3 233 · Phase 4 18
First in 1993; this study’s year is marked. 29 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,191 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 273 across the 580 interventional studies, 580 across the 92 observational. Of the 446 that completed or were terminated, 191 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
396 of 678 have an industry lead sponsor. The 10 most frequent:
North Eastern German Society of Gynaecological Oncology is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
North Eastern German Society of Gynaecological Oncology has 2 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
45 of the studies in Breast Neoplasms with a site in Germany that are under way reach primary completion within a year, 16 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03595592Phase 3Fondazione MichelangeloNeoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | 2026-12-15 |
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT05696626Phase 3LeonaBioEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
Add all 45 to your calendar (.ics) → With an account.
Among the 678 studies in Breast Neoplasms with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Systematic assessment of survival data of patients who have been tested with EndoPredict®; prospective proof that patients with low risk classification by EndoPredict® (EPclin) can safely forgo chemotherapy and be treated with endocrine therapy alone.
The goal of the study is to receive current and comprehensive information about the diseasefree (remote metastasis free and recurrence free) interval of EndoPredict® low risk patients.
The study is organized and managed by the NOGGO e.V. (North Eastern German Society of Gynaecological Oncology e.V.) study coordination office under the existing and efficient infrastructure. All patients who receive gene expression analysis with EndoPredict® and satisfy the remaining inclusion / exclusion criteria may participate in the study. Data collection is prospective and non-interventional. The recruitment of the required patients is expected to take a maximum of 36 months .
It must be emphasized that the study is data collection only and not an interventional study. This means that the choice and implementation of the therapy as well as the treatment assessments and frequency during and after the treatment can only be determined by the Investigator.
The decision to participate in the study is independent of the patient´s therapy within the framework of a study. Patient data will be recorded at the time of inclusion and once a year thereafter. Patient follow-up will be by phone from the second year onward.
Primary objective is to show that female patients who have been tested as "low risk" by EPclin and have been treated with endocrine therapy only for at least 5 years have a 10-year DMFS rate > 90% (lower boundary of the one-sided 95% confidence interval).
Secondary objectives comprise the evaluation of DMFS (distant metastasis free survival) , DFS (disease free survival) and OS (overall survival) rates at different time points and for different groups. Assessment of the given chemotherapy regimens and the given endocrine therapy will be performed and the proportions of patients will be determined with respect to the received treatment and its duration in different groups. Furthermore, the proportion of patients in whom the tumor board recommendation follows the EndoPredict® result and the proportion of patients actually treated according to EndoPredict® result will be determined.
The association between outcome and treatment, EPclin, EP, and classical prognostic factors will be investigated in different groups of patients. The correlation and concordance between EPclin calculations derived from biopsies and surgical specimens will be assessed.
Patients with primary stage I or Ii breast cancer who met all inclusin and no exclusion criteria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with primary invasive breast cancer, Stage I/II; ER positive, HER2 (human epidermal growth factor receptor 2) negative, N0-N1, T1-T3, tested with EndoPredict®, age over 18 years, informed consent
Other: Observation
Visit 1 Informed consent Medical history Demographics Result of EndoPredict® Test Status of menopause Disease status Tumor board decision Planned anti-tumor-therapy Visit 2, 1 year after inclusion This visit will be documented at the study site Status of menopause Disease status Anti-tumor therapy Survival Following visits For these visits, patients will be asked directly through the Center for Clinical Trials of the Philipps-University Marburg (KKS Marburg) via phone. Status of Menopause Disease status Anti-tumor therapy Survival Treatment after end of the study The patient will be treated during and after end of study by physician's choice.
Distant metastasis free survival
To show that female patients who have been tested as "low risk" by EndoPredict® (EPclin) and have been treated with endocrine therapy only for at least 5 years have a 10-year distant metastasis-free survival (DMFS) \> 90 % (lower boundary of the one-sided 95 % confidence interval)
Time frame: 10 years
DMFS "low risk"
Assessment of DMFS of patients with EPclin "low risk" (or EP "low risk" \[EP score \<5\] if EPclin cannot be calculated after surgery in the neoadjuvant setting) (in all patients, in the relevant target group and separately in men and women and in pre- and postmenopausal women with regard to treatment).
Time frame: 3, 5 and 10 years
DFS "low risk"
Assessment of DFS of patients with EPclin "low risk" (or EP "low risk" \[EP score \<5\] if EPclin cannot be calculated after surgery in the neoadjuvant setting) (in all patients, in the relevant target group and separately in men and women and in pre- and postmenopausal women with regard to treatment).
Time frame: 3, 5 and 10 years
OS "low risk"
Assessment of OS of patients with EPclin "low risk" (or EP "low risk" \[EP score \<5\] if EPclin cannot be calculated after surgery in the neoadjuvant setting) (in all patients, in the relevant target group and separately in men and women and in pre- and postmenopausal women with regard to treatment).
Time frame: 3, 5 and 10 years
DMFS "high risk"
Assessment of DMFS of patients with EPclin "high risk" in all patients and separated in men and women as well as pre- and postmenopausal women with regard to treatment).
Time frame: 3, 5 and 10 years
DFS "high risk"
Assessment of DFS of patients with EPclin "high risk" in all patients and separated in men and women as well as pre- and postmenopausal women with regard to treatment).
Time frame: 3, 5 and 10 years
OS "high risk"
Assessment of OS of patients with EPclin "high risk" in all patients and separated in men and women as well as pre- and postmenopausal women with regard to treatment).
Time frame: 3, 5 and 10 years
DMFS "high risk + low risk"
DMFS for patients who have / have not been treated according to EPclin/ EP result (all patients and subgroup analyses as specified in secondary objectives 1 and 2).
Time frame: 3, 5 and 10 years
DFS "high risk + low risk"
DFS for patients who have / have not been treated according to EPclin/ EP result (all patients and subgroup analyses as specified in secondary objectives 1 and 2).
Time frame: 3, 5 and 10 years
OS "high risk + low risk"
OS for patients who have / have not been treated according to EPclin/ EP result (all patients and subgroup analyses as specified in secondary objectives 1 and 2).
Time frame: 3, 5 and 10 years
Portion of patients tumor board follows the EndoPredict® result
Assessment of the proportion of patients in whom the tumor board follows the EndoPredict® result in regard to treatment recommendation (in all patients and separately for men and women).
Time frame: 1 year
Portion of patient treated according EndoPredict® result
Assessment of the proportion of patients who were actually treated according to the EndoPredict® result (in all patients and separately for men and women).
Time frame: 1 year
Prognostic Performance of classical prognostic factors compared to EndoPredict®
Assessment of the classical prognostic factors tumor size, nodal status, grading, quantitative estrogen receptor, quantitative progesterone receptor and quantitative Ki67 and evaluation of their prognostic performance compared to EPclin and EP in univariate and multivariate analyses of DMFS, DFS, OS (in all patients, separately for men and women, only in patients who have been treated according to the EndoPredict® result).
Time frame: 3, 5 and 10 years
DMFS "low risk vs. high risk"
Assessment of DMFS of patients with low risk vs. high risk as defined by national (German S3) and international (St. Gallen Consensus) guidelines based on IHC (immunohistochemistry)-classification.
Time frame: 3, 5 and 10 years
DFS "low risk vs. high risk"
Assessment of DFS of patients with low risk vs. high risk as defined by national (German S3) and international (St. Gallen Consensus) guidelines based on IHC-classification.
Time frame: 3, 5 and 10 years
OS "low risk vs. high risk"
Assessment of OS of patients with low risk vs. high risk as defined by national (German S3) and international (St. Gallen Consensus) guidelines based on IHC-classification.
Time frame: 3, 5 and 10 years
DMFS of patient proportion of EPclin low and high risk patients in Ki67 low, intermediate and high tumors
Assessment of proportion of EPclin low and high risk patients in Ki67 low, intermediate and high tumors, respectively, and stratified analysis of DMFS of patients with ki67-values low (≤ 10%)/ intermediate (11-24%)/ high (≥ 25%) and EPclin low risk vs high risk.
Time frame: 3, 5 and 10 years
DFS of patient proportion of EPclin low and high risk patients in Ki67 low, intermediate and high tumors
Assessment of proportion of EPclin low and high risk patients in Ki67 low, intermediate and high tumors, respectively, and stratified analysis of DFS of patients with ki67-values low (≤ 10%)/ intermediate (11-24%)/ high (≥ 25%) and EPclin low risk vs high risk.
Time frame: 3, 5 and 10 years
OS of patient proportion of EPclin low and high risk patients in Ki67 low, intermediate and high tumors
Assessment of proportion of EPclin low and high risk patients in Ki67 low, intermediate and high tumors, respectively, and stratified analysis of OS of patients with ki67-values low (≤ 10%)/ intermediate (11-24%)/ high (≥ 25%) and EPclin low risk vs high risk.
Time frame: 3, 5 and 10 years
DMFS "low risk vs. high risk" who have /have not been treated according to the S3 and St. Gallen guidelines
Assessment of DMFS after 3, 5 and 10 years of patients with low risk vs. high risk as defined by national (German S3) and international (St. Gallen Consensus) guidelines based on IHC-classification.
Time frame: 3, 5 and 10 years
DFS "low risk vs. high risk" who have /have not been treated according to the S3 and St. Gallen guidelines
Assessment of DFS of patients with low risk vs. high risk as defined by national (German S3) and international (St. Gallen Consensus) guidelines based on IHC-classification.
Time frame: 3, 5 and 10 years
OS "low risk vs. high risk" who have /have not been treated according to the S3 and St. Gallen guidelines
Assessment of OS of patients with low risk vs. high risk as defined by national (German S3) and international (St. Gallen Consensus) guidelines based on IHC-classification.
Time frame: 3, 5 and 10 years
Chemotherapy regimens
Description of the given chemotherapy regimens (in all patients and separately for men and women).
Time frame: 1 year
Given endocrine therapy
Description of the given endocrine therapy (in all patients and separately for men and women).
Time frame: 10 years
Duration of endocrine therapy
Duration of the endocrine therapy (in all patients and separately for men and women).
Time frame: 10 years
Proportion of patients with prolonged endocrine therapy
Proportion of patients with EPclin "low risk" and "high risk" respectively who received an extended (\> 5 years) endocrine therapy in all patients and separately for men and women).
Time frame: 10 years
DMFS for patients with 5 years of endocrine therapy vs. extended endocrine therapy
Assessment of DMFS according to EPclin / EP risk class for patients who have received an endocrine therapy for 5 years vs. patients who received an extended endocrine therapy (\> 5 years).
Time frame: 10 years
DFS for patients with 5 years of endocrine therapy vs. extended endocrine therapy
Assessment of DFS according to EPclin / EP risk class for patients who have received an endocrine therapy for 5 years vs. patients who received an extended endocrine therapy (\> 5 years).
Time frame: 10 years
OS for patients with 5 years of endocrine therapy vs. extended endocrine therapy
Assessment of OS according to EPclin / EP risk class for patients who have received an endocrine therapy for 5 years vs. patients who received an extended endocrine therapy (\> 5 years).
Time frame: 10 years
Correlation ( pT- and pN data vs. ciT and ciN-data)
Assessment of the correlation between EPclin, that has been calculated with pT- (pathological tumor size) and pN (pathological nodal status) data and the EPclin based on ciT (clinical/ imaging tumor size) and ciN (clinical/imaging nodal status)-data (in all patients and separately for men and women).
Time frame: 1 year
Concordance ( pT- and pN data vs. ciT and ciN-data)
Assessment of the concordance between EPclin, that has been calculated with pT- and pN data and the EPclin based on ciT and ciN-data (in all patients and separately for men and women).
Time frame: 1 year
Plan to share: No
Started Jul 2018 (actual). Primary completion is estimated for Oct 2032, 170 months after the start.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 170 months is above that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
North Eastern German Society of Gynaecological Oncology